Monitoring systemic lupus erythematosus in standard clinical care

Best Practice and Research: Clinical Rheumatology

Volumn 21, Issue 4, 2007, Pages 687-697

  Petri, Michelle ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

flare; organ damage; SLE

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIBIOTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYCHLOROQUINE; LEUPRORELIN; PREDNISONE; VITAMIN D;

AUTOIMMUNE DISEASE; AVASCULAR NECROSIS; BONE NECROSIS; CARDIOVASCULAR DISEASE; CATARACT; CLINICAL TRIAL; COGNITIVE DEFECT; CORTICOSTEROID INDUCED OSTEOPOROSIS; DISEASE ACTIVITY; DISEASE COURSE; FRAGILITY FRACTURE; HUMAN; HYPERCOAGULABILITY; JAW DISEASE; KIDNEY INJURY; LABORATORY TEST; LOW DRUG DOSE; OSTEOPOROSIS; PATIENT MONITORING; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PREMATURE OVARIAN FAILURE; PRIORITY JOURNAL; PROTEINURIA; QUALITY OF LIFE; RETINOPATHY; REVIEW; STROKE; SYSTEMIC LUPUS ERYTHEMATOSUS;

DATA COLLECTION; DISEASE MANAGEMENT; GLUCOCORTICOIDS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MEDICAL RECORDS; PHYSICAL EXAMINATION; PREDNISONE; QUALITY OF LIFE;

EID: 34547485022     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2007.01.003     Document Type: Review

References (45)

1. Barr S., Zonana-Nacach A., Magder L., and Petri M. Patterns of disease activity in systemic lupus erythematosus. Arthritis and Rheumatism 42 (1999) 2682-2688
2. Ho A., Magder L., Barr S., and Petri M. Decreases in anti-double stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis and Rheumatism 44 (2001) 2342-2349
3. Ho A., Magder L.S., Barr S.G., and Petri M.A. A decrease in complement is associated with increased renal and hematologic flares in patients with systemic lupus erythematosus. Arthritis and Rheumatism 44 (2001) 2350-2357
4. Gladman D.D., Hirani N., Ibanez D., and Urowitz M.B. Clinically active serologically quiescent systemic lupus erythematosus. The Journal of Rheumatology 30 9 (2003) 1960-1962
5. Buyon J.P., and Clancy R.M. Neonatal lupus: basic research and clinical perspectives. Rheumatic Diseases Clinics of North America 31 2 (2005) 299-313 vii
6. Cnossen J.S., de Ruyter-Hanhijarvi H., van der Post J.A., et al. Accuracy of serum uric acid determination in predicting pre-eclampsia: a systematic review. Acta Obstetricia et Gynecologica Scandinavica 85 5 (2006) 519-525
7. Clowse M.E., Magder L.S., Witter F., and Petri M. The impact of increased lupus activity on obstetric outcomes. Arthritis and Rheumatism 52 2 (2005) 514-521
8. The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis and Rheumatism 54 2 (2006) 421-432
9. Middendorf D.F., Hebert L.A., Zager R.A., et al. Simple method for monitoring 24-hour urinary urea nitrogen excretion. The Journal of Laboratory and Clinical Medicine 108 6 (1986) 577-580
10. Christopher-Stine L., Petri M., Astor B.C., and Fine D. Urine protein-to-creatinine ratio is a reliable measure of proteinuria in lupus nephritis. The Journal of Rheumatology 31 8 (2004) 1557-1559
11. Petri M., Hellmann D., and Hochberg M. Validity and reliability of lupus activity measures in the routine clinic setting. The Journal of Rheumatology 19 (1992) 53-59
12. Petri M., Kim M.Y., Kalunian K.C., et al. Combined oral contraceptives in women with systemic lupus erythematosus. The New England Journal of Medicine 353 (2005) 2550-2558
13. Ibanez D., Gladman D.D., and Urowitz M.B. Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE. The Journal of Rheumatology 32 5 (2005) 824-827
14. Hay E.M., Bacon P.A., Gordon C., et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. The Quarterly Journal of Medicine 86 7 (1993) 447-458
15. Yee C.S., Farewell V., Isenberg D.A., et al. Revised British Isles Lupus Assessment Group 2004 index: a reliable tool for assessment of systemic lupus erythematosus activity. Arthritis and Rheumatism 54 10 (2006) 3300-3305
16. Gladman D., Ginzler E., Goldsmith C., et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College Rheumatology damage index for sytemic lupus erythematosus. Arthritis and Rheumatism 39 (1996) 363-369
17. Zonana-Nacach A., Barr S.G., Magder L.S., and Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis and Rheumatism 43 (2000) 1801-1808
18. Recommendations for the prevention and treatment of glucocorticoid- induced osteoporosis. American College of Rheumatology Task Force on Osteoporosis Guidelines. Arthritis and Rheumatism 39 11 (1996) 1791-1801
19. Nair K.S., Rizza R.A., O'Brien P., et al. DHEA in elderly women and DHEA or testosterone in elderly men. The New England Journal of Medicine 355 16 (2006) 1647-1659
20. Petri M. Musculoskeletal complications of systemic lupus erythematosus in the Hopkins Lupus Cohort:an update. Arthritis Care and Research 8 (1995) 137-145
21. Mont M.A., Fairbank A.C., Petri M., and Hungerford D.S. Core decompression for osteonecrosis of the femoral head in systemic lupus erythematosus. Clinical Orthopaedics Jan (1997) 91-97
22. Bamias A., Kastritis E., Bamia C., et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. Journal of Clinical Oncology 23 34 (2005) 8580-8587
23. Ginsburg K.S., Liang M.H., Newcomer L., et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Annals of Internal Medicine 117 (1992) 997-1002
24. Petri M., Roubenoff R., Dallal G.E., et al. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 348 (1996) 1120-1124
25. McMahon J.A., Green T.J., Skeaff C.M., et al. A controlled trial of homocysteine lowering and cognitive performance. The New England Journal of Medicine 354 26 (2006) 2764-2772
26. Bazzano L.A., Reynolds K., Holder K.N., and He J. Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. JAMA: The Journal of the American Medical Association 296 22 (2006) 2720-2726
27. McLaurin E.Y., Holliday S.L., Williams P., and Brey R.L. Predictors of cognitive dysfunction in patients with systemic lupus erythematosus. Neurology 64 2 (2005) 297-303
28. Hanly J.G., Hong C., Smith S., and Fisk J.D. A prospective analysis of cognitive function and anticardiolipin antibodies in systemic lupus erythematosus. Arthritis and Rheumatism 42 4 (1999) 728-734
29. Menon S., Jameson-Shortall E., Newman S.P., et al. A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus. Arthritis and Rheumatism 42 4 (1999) 735-741
30. Leritz E., Brandt J., Minor M., et al. Neuropsychological functioning and its relationship to antiphospholipid antibodies in patients with systemic lupus erythematosus. Journal of Clinical and Experimental Neuropsychology 24 4 (2002) 527-533
31. Woolf C.J., and Salter M.W. Neuronal plasticity: increasing the gain in pain. Science 288 5472 (2000) 1765-1769
32. Marmor M.F. New American Academy of Ophthalmology recommendations on screening for hydroxychloroquine retinopathy. Arthritis and Rheumatism 48 6 (2003) 1764
33. Urowitz M.B., Bookman A.A.M., Koehler B.E., et al. The bimodal mortality pattern of systemic lupus erythematosus. The American Journal of Medicine 60 (1976) 221-225
34. Manzi S., Meilahn E.N., Rairie J.E., et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. American Journal of Epidemiology 145 5 (1997) 408-415
35. Esdaile J.M., Abrahamowicz M., Grodzicky T., et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis and Rheumatism 44 10 (2001) 2331-2337
36. Chobanian A.V., Bakris G.L., Black H.R., et al. The Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA: The Journal of the American Medical Association 289 19 (2003) 2560-2572
37. Report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. Archives of Internal Medicine 148 (1988) 36-39
38. Shidham G., and Hebert L.A. Timed urine collections are not needed to measure urine protein excretion in clinical practice. American Journal of Kidney Diseases 47 1 (2006) 8-14
39. Hebert L.A. Optimizing ACE-inhibitor therapy for chronic kidney disease. The New England Journal of Medicine 354 2 (2006) 189-191
40. Cooper W.O., Hernandez-Diaz S., Arbogast P.G., et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. The New England Journal of Medicine 354 23 (2006) 2443-2451
41. Boumpas D.T., Austin III H.A., Vaughan E.M., et al. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Annals of Internal Medicine 119 (1993) 366-369
42. Somers E.C., Marder W., Christman G.M., et al. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis and Rheumatism 52 9 (2005) 2761-2767
43. Dooley M.A., Patterson C.C., Hogan S.L., et al. Preservation of ovarian function using depot leuprolide acetate during cyclophosphamide therapy for severe lupus nephritis. Arthritis and Rheumatism 43 (2000) 2858 [ abstract]
44. Akkasilpa S., Goldman D., Magder L.S., and Petri M. Number of fibromyalgia tender points is associated with health status in patients with systemic lupus erythematosus. The Journal of Rheumatology 32 1 (2005) 48-50
45. Goldenberg D.L., Burckhardt C., and Crofford L. Management of fibromyalgia syndrome. JAMA: The Journal of the American Medical Association 292 19 (2004) 2388-2395